Search results
Showing 646 to 660 of 2548 results for methods
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
In development Reference number: GID-TA11154 Expected publication date: TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Awaiting development Reference number: GID-TA10638 Expected publication date: TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]
In development Reference number: GID-TA11630 Expected publication date: TBC
In development Reference number: GID-TA11519 Expected publication date: 12 June 2026
In development Reference number: GID-TA11675 Expected publication date: TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
In development Reference number: GID-TA11410 Expected publication date: TBC
In development Reference number: GID-TA11497 Expected publication date: TBC
Awaiting development Reference number: GID-TA11343 Expected publication date: TBC
In development Reference number: GID-TA11336 Expected publication date: TBC
Artificial intelligence software to help detect and characterise colorectal polyps
In development Reference number: GID-DG10118 Expected publication date: TBC
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
In development Reference number: GID-TA11440 Expected publication date: TBC
In development Reference number: GID-TA11531 Expected publication date: TBC
This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.
In development Reference number: GID-TA11115 Expected publication date: TBC